CryoLife (NYSE:CRY) CAO Amy Horton sold 4,000 shares of CryoLife stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $25.94, for a total transaction of $103,760.00. Following the sale, the chief accounting officer now directly owns 98,959 shares in the company, valued at approximately $2,566,996.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
CryoLife traded down $0.25, hitting $25.20, during midday trading on Friday, MarketBeat.com reports. 74,600 shares of the stock were exchanged, compared to its average volume of 114,019. CryoLife has a 1 year low of $16.80 and a 1 year high of $26.25. The company has a market capitalization of $926.80 million, a price-to-earnings ratio of 63.00 and a beta of 0.73. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.07 and a quick ratio of 3.09.
CryoLife (NYSE:CRY) last released its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. CryoLife had a negative net margin of 1.15% and a positive return on equity of 4.55%. The firm had revenue of $61.95 million for the quarter, compared to the consensus estimate of $60.30 million. During the same quarter in the previous year, the firm posted $0.09 EPS. The firm’s quarterly revenue was up 37.5% on a year-over-year basis. analysts forecast that CryoLife will post 0.11 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on CRY shares. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price target (up previously from $25.00) on shares of CryoLife in a research note on Friday, March 9th. Zacks Investment Research raised shares of CryoLife from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Northland Securities reaffirmed a “buy” rating and set a $23.50 price target on shares of CryoLife in a research note on Thursday, March 8th. Finally, ValuEngine downgraded shares of CryoLife from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $26.63.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Tennessee Treasury Department increased its position in shares of CryoLife by 18.7% in the 4th quarter. State of Tennessee Treasury Department now owns 26,388 shares of the medical equipment provider’s stock worth $505,000 after purchasing an additional 4,152 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of CryoLife by 13.0% in the 1st quarter. New York State Common Retirement Fund now owns 36,500 shares of the medical equipment provider’s stock worth $732,000 after purchasing an additional 4,200 shares during the last quarter. Monarch Partners Asset Management LLC increased its position in shares of CryoLife by 24.9% in the 4th quarter. Monarch Partners Asset Management LLC now owns 22,730 shares of the medical equipment provider’s stock worth $435,000 after purchasing an additional 4,530 shares during the last quarter. California Public Employees Retirement System increased its position in shares of CryoLife by 6.6% in the 3rd quarter. California Public Employees Retirement System now owns 95,172 shares of the medical equipment provider’s stock worth $2,160,000 after purchasing an additional 5,872 shares during the last quarter. Finally, Thomson Horstmann & Bryant Inc. increased its position in shares of CryoLife by 1.8% in the 1st quarter. Thomson Horstmann & Bryant Inc. now owns 345,581 shares of the medical equipment provider’s stock worth $6,928,000 after purchasing an additional 6,171 shares during the last quarter. 74.11% of the stock is owned by institutional investors.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for CryoLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife and related companies with MarketBeat.com's FREE daily email newsletter.